Cerebroside-Sulfatase

"Cerebroside-Sulfatase" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

An enzyme that catalyzes the hydrolysis of cerebroside 3-sulfate (sulfatide) to yield a cerebroside and inorganic sulfate. A marked deficiency of arylsulfatase A, which is considered the heat-labile component of cerebroside sulfatase, has been demonstrated in all forms of metachromatic leukodystrophy (LEUKODYSTROPHY, METACHROMATIC). EC 3.1.6.8.

Descriptor ID

D002553

MeSH Number(s)

D08.811.277.352.827.070.250

Concept/Terms

Cerebroside-Sulfatase

Below are MeSH descriptors whose meaning is more general than "Cerebroside-Sulfatase".

Chemicals and Drugs [D]
Enzymes and Coenzymes [D08]
Enzymes [D08.811]
Hydrolases [D08.811.277]
Esterases [D08.811.277.352]
Sulfatases [D08.811.277.352.827]
Arylsulfatases [D08.811.277.352.827.070]
Cerebroside-Sulfatase [D08.811.277.352.827.070.250]

Below are MeSH descriptors whose meaning is related to "Cerebroside-Sulfatase".

Below are MeSH descriptors whose meaning is more specific than "Cerebroside-Sulfatase".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Cerebroside-Sulfatase" by people in Harvard Catalyst Profiles by year, and whether "Cerebroside-Sulfatase" was a major or minor topic of these publication.

Bar chart showing 13 publications over 8 distinct years, with a maximum of 4 publications in 2013

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2005	0	1	1
2006	1	1	2
2009	1	0	1
2012	0	1	1
2013	4	0	4
2015	1	0	1
2021	0	1	1
2022	1	1	2

Below are the most recent publications written about "Cerebroside-Sulfatase" by people in Profiles.

Understanding caregiver descriptions of initial signs and symptoms to improve diagnosis of metachromatic leukodystrophy. Orphanet J Rare Dis. 2022 10 04; 17(1):370.

View in: PubMed
Lentiviral haematopoietic stem-cell gene therapy for early-onset metachromatic leukodystrophy: long-term results from a non-randomised, open-label, phase 1/2 trial and expanded access. Lancet. 2022 01 22; 399(10322):372-383.

View in: PubMed
Toward Reference Intervals of ARSA Activity in the Cerebrospinal Fluid: Implication for the Clinical Practice of Metachromatic Leukodystrophy. J Appl Lab Med. 2021 03 01; 6(2):354-366.

View in: PubMed
Mutation Update of ARSA and PSAP Genes Causing Metachromatic Leukodystrophy. Hum Mutat. 2016 Jan; 37(1):16-27.

View in: PubMed
Critical issues for the proper diagnosis of Metachromatic Leukodystrophy. Gene. 2014 Mar 10; 537(2):348-51.

View in: PubMed
A new analytical bench assay for the determination of arylsulfatase a activity toward galactosyl-3-sulfate ceramide: implication for metachromatic leukodystrophy diagnosis. Anal Chem. 2014 Jan 07; 86(1):473-81.

View in: PubMed
Broadening the indications for hematopoietic stem cell genetic therapies. Cell Stem Cell. 2013 Sep 05; 13(3):263-4.

View in: PubMed
Gene therapy: primed for take-off. Nature. 2013 Aug 15; 500(7462):280-2.

View in: PubMed
Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science. 2013 Aug 23; 341(6148):1233158.

View in: PubMed
Expert recommendations for the laboratory diagnosis of MPS VI. Mol Genet Metab. 2012 May; 106(1):73-82.

View in: PubMed

Related Networks

People

Explore

Similar Concepts

Top Journals

Hum Mutat
Mol Genet Metab
J Surg Res
Gene
Cytogenet Cell Genet
Circ Shock
Cell Stem Cell
Ann Neurol
Anal Chem
Am J Ophthalmol